Impact of Vitamin C on Biomarkers of Neurologic Injury in Survivors of Cardiac Arrest
Primary Purpose
Heart Arrest, Out-Of-Hospital, Biomarkers, Oxidative Stress
Status
Unknown status
Phase
Phase 2
Locations
Slovenia
Study Type
Interventional
Intervention
Vitamin C
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Heart Arrest, Out-Of-Hospital focused on measuring vitamin C, biomarkers, brain injury, cardiac arrest
Eligibility Criteria
Inclusion Criteria:
- comatose survivors of out-of-hospital arrest
Exclusion Criteria:
- patients with trauma, asphyxia, drowning or electrocution as a cause of cardiac arrest
- history of oxalate nephropathy or nephrolithiasis, glucose-6-phosphate dehydrogenase deficiency, and hemochromatosis
- pregnancy
Sites / Locations
- University Medical Centre Maribor
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Vitamin C
Placebo
Arm Description
Group of patients that will receive vitamin C (ascorbic acid 1,5 g mixed with 0,9 % solution of sodium chloride 100 ml every 12 hours for 4 days intravenously).
Group of patients that will receive placebo (0,9 % solution of sodium chloride 100 ml every 12 hours for 4 days intravenously).
Outcomes
Primary Outcome Measures
Biomarkers of neurological injury
Serum levels of protein S-100b and neuron-specific enolase.
Secondary Outcome Measures
Brain imaging (CT and MRI)
Unconscious survivors will have first brain imaging on the 3rd day, if still unconscious, second imaging around the 10th day. Imaging results will be descriptive (normal or pathological with signs of global ischemic injury: generalised edema, reduced grey and white matter differentiation, obliteration of the sulci). Second image will be compared to the first.
Electroencephalography (EEG)
Unconscious survivors will have first EEG on the 3rd day, if still unconscious, second imaging around the 10th day. EEG results will be descriptive (normal or pathological with background suppression with or without periods of bursts, with or without response to external stimulus and similar patterns). Second EEG will be compared to the first.
Evaluation of pupils
Pupils size, reactivity and symmetry on admission and during hospitalisation will be observed daily.
Evaluation of involuntary movements
The presence of involuntary movements will be observed daily.
Evaluation of GCS
Level of consciousness will be determined daily with Glasgow Coma Scale (GCS).
Evaluation of FOUR
Level of consciousness will be determined daily with Full Outline of UnResponsiveness (FOUR) score.
Cerebral Performance Category
Cerebral Performance Category (CPC) at discharge will be recorded.
Left ventricular ejection fraction
Left ventricular ejection fraction (first, last, best, worst), determined by ultrasound will be noted.
Arrhythmias
Presence of arrhythmias and the need for treating them will be recorded.
Evaluation of heart failure
Clinical evaluation of heart failure according to Killip-Kimball classification will be performed (worst result).
Serum troponin level
Serum troponin levels will be determined (on admission, minimal, maximal).
Serum Brain natriuretic peptide
Serum brain natriuretic peptide levels will be determined (on admission, minimal, maximal).
Vasopressor and/or inotrope need
The need for vasopressors and inotropes will be noted, along with the name of the substance, maximal dosage and duration.
Mechanical ventilation
Days and hours of mechanical ventilation will be noted.
Kidney failure
The need for renal replacement therapy (and consecutive day of such therapy) will be recorded.
Serum urea levels
Serum levels of urea will be recorded (on admission, minimal, maximal).
Serum creatinine levels
Serum creatinine levels will be recorded (on admission, minimal, maximal).
Serum C-reactive protein levels
Serum C-reactive protein levels will be determined (on admission, minimal, maximal).
Serum procalcitonin levels
Serum procalcitonin levels will be determined (on admission, minimal, maximal).
Full Information
NCT ID
NCT04563000
First Posted
September 10, 2020
Last Updated
September 21, 2020
Sponsor
University Medical Centre Maribor
1. Study Identification
Unique Protocol Identification Number
NCT04563000
Brief Title
Impact of Vitamin C on Biomarkers of Neurologic Injury in Survivors of Cardiac Arrest
Official Title
Impact of Vitamin C on Biomarkers of Neurologic Injury in Patients With Return of Spontaneous Circulation After Out-of-Hospital Cardiac Arrest
Study Type
Interventional
2. Study Status
Record Verification Date
September 2020
Overall Recruitment Status
Unknown status
Study Start Date
October 1, 2020 (Anticipated)
Primary Completion Date
October 31, 2022 (Anticipated)
Study Completion Date
December 31, 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Medical Centre Maribor
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Out-of-hospital cardiac arrest (OHCA) is one of the leading cause of death in the world. In Slovenia approximately 25% of resuscitated patients survives to discharge from hospitals, usually with poorer functional status.
One of key pathophysiological process responsible for poorer functional status is global hypoxic-ischemic injury, which is two-stage. Primary stage occurs immediately after cardiac arrest due to cessation of blood flow. With return of spontaneous circulation a secondary injury occurs, of which the leading process is an imbalance between oxygen delivery and consumption. Reperfusion exposes ischemic tissue to oxygen, resulting in the formation of large amounts of highly reactive oxygen species (ROS) within minutes. ROS lead to oxidative stress, which causes extensive damage to cell structures and leads to cell death. Consequently, necrosis and apoptosis are responsible for organ dysfunction and functional outcome of these patients.
Such injury of neural tissue causes brain damage, which is ultimately responsible for poor neurological and thus functional outcome of OHCA survivors. The extent of brain damage can be determined in several ways: clinically by assessing quantitative and qualitative consciousness and the presence of involuntary movements in an unconscious patient, by assessing activity on electroencephalographic record, by imaging of the brain with computed tomography and magnetic resonance imaging, as well as by assessing levels of biological markers of brain injury. Of the latter, the S-100b protein and neuron-specific enolase have been shown to be suitable for such assessment.
Oxidative stress is counteracted by the body with endogenous antioxidants that balance excess free radicals and stabilize cellular function. Vitamin C (ascorbic acid) is the body's main antioxidant and is primarily consumed during oxidative stress. Large amounts of ROS rapidly depletes the body's vitamin C stores.
Humans cannot synthesise vitamin C and enteral uptake of vitamin C is limited by transporter saturation. On the other hand, parenteral (venous) dosing of vitamin C can achieve concentrations of vitamin C above physiological and thus produce a stronger antioxidant effect. The beneficial effect of parenteral dosing of vitamin C has been establish in several preclinical and clinical studies in patients with ischemic stroke and cardiac arrest.
The investigators hypothesize that there is a similarly beneficial effect of vitamin C in survivors of OHCA.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Arrest, Out-Of-Hospital, Biomarkers, Oxidative Stress, Neurological Injury
Keywords
vitamin C, biomarkers, brain injury, cardiac arrest
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
150 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Vitamin C
Arm Type
Experimental
Arm Description
Group of patients that will receive vitamin C (ascorbic acid 1,5 g mixed with 0,9 % solution of sodium chloride 100 ml every 12 hours for 4 days intravenously).
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Group of patients that will receive placebo (0,9 % solution of sodium chloride 100 ml every 12 hours for 4 days intravenously).
Intervention Type
Drug
Intervention Name(s)
Vitamin C
Intervention Description
Ascorbic acid 1,5 g intravenously every 12-hours for 4 consecutive days
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
0,9 % solution of sodium chloride 100 ml intravenously every 12-hours for 4 consecutive days
Primary Outcome Measure Information:
Title
Biomarkers of neurological injury
Description
Serum levels of protein S-100b and neuron-specific enolase.
Time Frame
5th day
Secondary Outcome Measure Information:
Title
Brain imaging (CT and MRI)
Description
Unconscious survivors will have first brain imaging on the 3rd day, if still unconscious, second imaging around the 10th day. Imaging results will be descriptive (normal or pathological with signs of global ischemic injury: generalised edema, reduced grey and white matter differentiation, obliteration of the sulci). Second image will be compared to the first.
Time Frame
3rd-10th day
Title
Electroencephalography (EEG)
Description
Unconscious survivors will have first EEG on the 3rd day, if still unconscious, second imaging around the 10th day. EEG results will be descriptive (normal or pathological with background suppression with or without periods of bursts, with or without response to external stimulus and similar patterns). Second EEG will be compared to the first.
Time Frame
3rd-10th day
Title
Evaluation of pupils
Description
Pupils size, reactivity and symmetry on admission and during hospitalisation will be observed daily.
Time Frame
from admission until 14 days or till discharge from ICU or death (whatever comes first)
Title
Evaluation of involuntary movements
Description
The presence of involuntary movements will be observed daily.
Time Frame
from admission until 14 days or till discharge from ICU or death (whatever comes first)
Title
Evaluation of GCS
Description
Level of consciousness will be determined daily with Glasgow Coma Scale (GCS).
Time Frame
from admission until 14 days or till discharge from ICU or death (whatever comes first)
Title
Evaluation of FOUR
Description
Level of consciousness will be determined daily with Full Outline of UnResponsiveness (FOUR) score.
Time Frame
from admission until 14 days or till discharge from ICU or death (whatever comes first)
Title
Cerebral Performance Category
Description
Cerebral Performance Category (CPC) at discharge will be recorded.
Time Frame
from admission till discharge from ICU or death (whatever comes first)
Title
Left ventricular ejection fraction
Description
Left ventricular ejection fraction (first, last, best, worst), determined by ultrasound will be noted.
Time Frame
from admission until 14 days or till discharge from ICU or death (whatever comes first)
Title
Arrhythmias
Description
Presence of arrhythmias and the need for treating them will be recorded.
Time Frame
from admission until 14 days or till discharge from ICU or death (whatever comes first)
Title
Evaluation of heart failure
Description
Clinical evaluation of heart failure according to Killip-Kimball classification will be performed (worst result).
Time Frame
from admission until 14 days or till discharge from ICU or death (whatever comes first)
Title
Serum troponin level
Description
Serum troponin levels will be determined (on admission, minimal, maximal).
Time Frame
from admission until 14 days or till discharge from ICU or death (whatever comes first)
Title
Serum Brain natriuretic peptide
Description
Serum brain natriuretic peptide levels will be determined (on admission, minimal, maximal).
Time Frame
from admission until 14 days or till discharge from ICU or death (whatever comes first)
Title
Vasopressor and/or inotrope need
Description
The need for vasopressors and inotropes will be noted, along with the name of the substance, maximal dosage and duration.
Time Frame
from admission until 14 days or till discharge from ICU or death (whatever comes first)
Title
Mechanical ventilation
Description
Days and hours of mechanical ventilation will be noted.
Time Frame
from admission until 14 days or till discharge from ICU or death (whatever comes first)
Title
Kidney failure
Description
The need for renal replacement therapy (and consecutive day of such therapy) will be recorded.
Time Frame
from admission until 14 days or till discharge from ICU or death (whatever comes first)
Title
Serum urea levels
Description
Serum levels of urea will be recorded (on admission, minimal, maximal).
Time Frame
from admission until 14 days or till discharge from ICU or death (whatever comes first)
Title
Serum creatinine levels
Description
Serum creatinine levels will be recorded (on admission, minimal, maximal).
Time Frame
from admission until 14 days or till discharge from ICU or death (whatever comes first)
Title
Serum C-reactive protein levels
Description
Serum C-reactive protein levels will be determined (on admission, minimal, maximal).
Time Frame
from admission until 14 days or till discharge from ICU or death (whatever comes first)
Title
Serum procalcitonin levels
Description
Serum procalcitonin levels will be determined (on admission, minimal, maximal).
Time Frame
from admission until 14 days or till discharge from ICU or death (whatever comes first)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
- comatose survivors of out-of-hospital arrest
Exclusion Criteria:
patients with trauma, asphyxia, drowning or electrocution as a cause of cardiac arrest
history of oxalate nephropathy or nephrolithiasis, glucose-6-phosphate dehydrogenase deficiency, and hemochromatosis
pregnancy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Andrej Markota, MD, PhD, Assist. Prof.
Phone
+38651311519
Email
andrej.markota@ukc-mb.si
First Name & Middle Initial & Last Name or Official Title & Degree
Matevž Privšek, MD
Phone
+38640642986
Email
matevz.privsek@icloud.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andrej Markota, MD, PhD, Assist. Prof.
Organizational Affiliation
University Medical Centre Maribor
Official's Role
Study Chair
Facility Information:
Facility Name
University Medical Centre Maribor
City
Maribor
ZIP/Postal Code
2000
Country
Slovenia
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andrej Markota, MD, PhD, Assist. Prof.
Phone
+38651311519
Email
andrej.markota@ukc-mb.si
First Name & Middle Initial & Last Name & Degree
Matevž Privšek, MD
Phone
+38640642986
Email
matevz.privsek@icloud.com
First Name & Middle Initial & Last Name & Degree
Matevž Privšek, MD
First Name & Middle Initial & Last Name & Degree
Andrej Markota, MD, PhD, Assist. Prof.
First Name & Middle Initial & Last Name & Degree
Matej Strnad, MD, PhD, Assoc. Prof.
First Name & Middle Initial & Last Name & Degree
Rok Petrovčič, MD
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
27321577
Citation
Grasner JT, Lefering R, Koster RW, Masterson S, Bottiger BW, Herlitz J, Wnent J, Tjelmeland IB, Ortiz FR, Maurer H, Baubin M, Mols P, Hadzibegovic I, Ioannides M, Skulec R, Wissenberg M, Salo A, Hubert H, Nikolaou NI, Loczi G, Svavarsdottir H, Semeraro F, Wright PJ, Clarens C, Pijls R, Cebula G, Correia VG, Cimpoesu D, Raffay V, Trenkler S, Markota A, Stromsoe A, Burkart R, Perkins GD, Bossaert LL; EuReCa ONE Collaborators. EuReCa ONE-27 Nations, ONE Europe, ONE Registry: A prospective one month analysis of out-of-hospital cardiac arrest outcomes in 27 countries in Europe. Resuscitation. 2016 Aug;105:188-95. doi: 10.1016/j.resuscitation.2016.06.004. Epub 2016 Jun 16. Erratum In: Resuscitation. 2016 Dec;109 :145-146.
Results Reference
background
PubMed Identifier
18963350
Citation
Nolan JP, Neumar RW, Adrie C, Aibiki M, Berg RA, Bottiger BW, Callaway C, Clark RS, Geocadin RG, Jauch EC, Kern KB, Laurent I, Longstreth WT, Merchant RM, Morley P, Morrison LJ, Nadkarni V, Peberdy MA, Rivers EP, Rodriguez-Nunez A, Sellke FW, Spaulding C, Sunde K, Hoek TV. Post-cardiac arrest syndrome: epidemiology, pathophysiology, treatment, and prognostication. A Scientific Statement from the International Liaison Committee on Resuscitation; the American Heart Association Emergency Cardiovascular Care Committee; the Council on Cardiovascular Surgery and Anesthesia; the Council on Cardiopulmonary, Perioperative, and Critical Care; the Council on Clinical Cardiology; the Council on Stroke. Resuscitation. 2008 Dec;79(3):350-79. doi: 10.1016/j.resuscitation.2008.09.017. Epub 2008 Oct 28.
Results Reference
background
PubMed Identifier
28403909
Citation
Sekhon MS, Ainslie PN, Griesdale DE. Clinical pathophysiology of hypoxic ischemic brain injury after cardiac arrest: a "two-hit" model. Crit Care. 2017 Apr 13;21(1):90. doi: 10.1186/s13054-017-1670-9.
Results Reference
background
PubMed Identifier
16864809
Citation
Wijdicks EF, Hijdra A, Young GB, Bassetti CL, Wiebe S; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: prediction of outcome in comatose survivors after cardiopulmonary resuscitation (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006 Jul 25;67(2):203-10. doi: 10.1212/01.wnl.0000227183.21314.cd.
Results Reference
background
PubMed Identifier
24795283
Citation
Calderon LM, Guyette FX, Doshi AA, Callaway CW, Rittenberger JC; Post Cardiac Arrest Service. Combining NSE and S100B with clinical examination findings to predict survival after resuscitation from cardiac arrest. Resuscitation. 2014 Aug;85(8):1025-9. doi: 10.1016/j.resuscitation.2014.04.020. Epub 2014 Apr 30.
Results Reference
background
PubMed Identifier
19535196
Citation
Shinozaki K, Oda S, Sadahiro T, Nakamura M, Abe R, Nakada TA, Nomura F, Nakanishi K, Kitamura N, Hirasawa H. Serum S-100B is superior to neuron-specific enolase as an early prognostic biomarker for neurological outcome following cardiopulmonary resuscitation. Resuscitation. 2009 Aug;80(8):870-5. doi: 10.1016/j.resuscitation.2009.05.005. Epub 2009 Jun 17.
Results Reference
background
PubMed Identifier
29558975
Citation
Spoelstra-de Man AME, Elbers PWG, Oudemans-van Straaten HM. Making sense of early high-dose intravenous vitamin C in ischemia/reperfusion injury. Crit Care. 2018 Mar 20;22(1):70. doi: 10.1186/s13054-018-1996-y.
Results Reference
background
PubMed Identifier
22332036
Citation
Levine M, Padayatty SJ, Espey MG. Vitamin C: a concentration-function approach yields pharmacology and therapeutic discoveries. Adv Nutr. 2011 Mar;2(2):78-88. doi: 10.3945/an.110.000109. Epub 2011 Mar 10.
Results Reference
background
PubMed Identifier
21953354
Citation
Tsai MS, Huang CH, Tsai CY, Chen HW, Lee HC, Cheng HJ, Hsu CY, Wang TD, Chang WT, Chen WJ. Ascorbic acid mitigates the myocardial injury after cardiac arrest and electrical shock. Intensive Care Med. 2011 Dec;37(12):2033-40. doi: 10.1007/s00134-011-2362-6. Epub 2011 Sep 28.
Results Reference
background
PubMed Identifier
24628750
Citation
Tsai MS, Huang CH, Tsai CY, Chen HW, Cheng HJ, Hsu CY, Chang WT, Chen WJ. Combination of intravenous ascorbic acid administration and hypothermia after resuscitation improves myocardial function and survival in a ventricular fibrillation cardiac arrest model in the rat. Acad Emerg Med. 2014 Mar;21(3):257-65. doi: 10.1111/acem.12335.
Results Reference
background
PubMed Identifier
11961055
Citation
Gao F, Yao CL, Gao E, Mo QZ, Yan WL, McLaughlin R, Lopez BL, Christopher TA, Ma XL. Enhancement of glutathione cardioprotection by ascorbic acid in myocardial reperfusion injury. J Pharmacol Exp Ther. 2002 May;301(2):543-50. doi: 10.1124/jpet.301.2.543.
Results Reference
background
PubMed Identifier
1583008
Citation
Nishinaka Y, Sugiyama S, Yokota M, Saito H, Ozawa T. The effects of a high dose of ascorbate on ischemia-reperfusion-induced mitochondrial dysfunction in canine hearts. Heart Vessels. 1992;7(1):18-23. doi: 10.1007/BF01745863.
Results Reference
background
PubMed Identifier
20170881
Citation
Basili S, Tanzilli G, Mangieri E, Raparelli V, Di Santo S, Pignatelli P, Violi F. Intravenous ascorbic acid infusion improves myocardial perfusion grade during elective percutaneous coronary intervention: relationship with oxidative stress markers. JACC Cardiovasc Interv. 2010 Feb;3(2):221-9. doi: 10.1016/j.jcin.2009.10.025.
Results Reference
background
PubMed Identifier
7863489
Citation
Dingchao H, Zhiduan Q, Liye H, Xiaodong F. The protective effects of high-dose ascorbic acid on myocardium against reperfusion injury during and after cardiopulmonary bypass. Thorac Cardiovasc Surg. 1994 Oct;42(5):276-8. doi: 10.1055/s-2007-1016504.
Results Reference
background
PubMed Identifier
9842436
Citation
Henry PT, Chandy MJ. Effect of ascorbic acid on infarct size in experimental focal cerebral ischaemia and reperfusion in a primate model. Acta Neurochir (Wien). 1998;140(9):977-80. doi: 10.1007/s007010050201.
Results Reference
background
PubMed Identifier
11573006
Citation
Huang J, Agus DB, Winfree CJ, Kiss S, Mack WJ, McTaggart RA, Choudhri TF, Kim LJ, Mocco J, Pinsky DJ, Fox WD, Israel RJ, Boyd TA, Golde DW, Connolly ES Jr. Dehydroascorbic acid, a blood-brain barrier transportable form of vitamin C, mediates potent cerebroprotection in experimental stroke. Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11720-4. doi: 10.1073/pnas.171325998.
Results Reference
background
PubMed Identifier
20885017
Citation
Lagowska-Lenard M, Stelmasiak Z, Bartosik-Psujek H. Influence of vitamin C on markers of oxidative stress in the earliest period of ischemic stroke. Pharmacol Rep. 2010 Jul-Aug;62(4):751-6. doi: 10.1016/s1734-1140(10)70334-0.
Results Reference
background
Learn more about this trial
Impact of Vitamin C on Biomarkers of Neurologic Injury in Survivors of Cardiac Arrest
We'll reach out to this number within 24 hrs